Search Results - "Cabeza‐Barrera, José"

Medication reconciliation at admission to surgical departments by González-García, Lorena, Salmerón-García, Antonio, García-Lirola, MªAngeles, Moya-Roldán, Susana, Belda-Rustarazo, Susana, Cabeza-Barrera, José

“…Rationale, aims and objectives We aim to determine the prevalence of reconciliation errors (REs) at admission to surgery departments, report their potential…”
Get full text

Trends in endpoint selection and result interpretation in advanced non‐small cell lung cancer clinical trials published between 2000 and 2012: A retrospective cohort study by Fernández‐López, Cristina, Calleja‐Hernández, Miguel Ángel, Balbino, Jaime Espín, Cabeza‐Barrera, José, Expósito‐Hernández, José

“…Background The objective of this review was to investigate trends in clinical trial design, specifically, the primary outcomes used, interpretation of results,…”
Get full text

Trends in phase III randomized controlled clinical trials on the treatment of advanced non‐small‐cell lung cancer by Fernández‐López, Cristina, Expósito‐Hernández, José, Arrebola‐Moreno, Juan Pedro, Calleja‐Hernández, Miguel Ángel, Expósito‐Ruíz, Manuela, Guerrero‐Tejada, Rosa, Linares, Isabel, Cabeza‐Barrera, José

“…The objective of this review was to analyze trends in outcomes and in the quality of phase III randomized controlled trials on advanced NSCLC published between…”
Get full text

Historical exposure to persistent organic pollutants and cardiovascular disease: A 15-year longitudinal analysis focused on pharmaceutical consumption in primary care by Pérez-Carrascosa, Francisco Miguel, Gómez-Peña, Celia, Echeverría, Ruth, Juan Jiménez Moleón, José, Manuel Melchor, Juan, García-Ruiz, Antonio, Luis Navarro-Espigares, José, Cabeza-Barrera, José, Martin-Olmedo, Piedad, Carlos Ortigosa-García, Juan, Arrebola, Juan Pedro

“…[Display omitted] •We explored longitudinal associations of POP exposure with cardiovascular disease.•Pharmaceutical consumption was used as a proxy for…”
Get full text

Pharmacogenetics of siponimod: A systematic review by Díaz-Villamarín, Xando, Piñar-Morales, Raquel, Barrero-Hernández, Francisco Javier, Antúnez-Rodríguez, Alba, Cabeza-Barrera, José, Morón-Romero, Rocío

“…Multiple sclerosis is a chronic inflammatory neurological disease, and siponimod (Mayzent) is the first oral treatment option for adult patients with secondary…”
Get full text

Azathioprine dose tailoring based on pharmacogenetic information: Insights of clinical implementation by Díaz-Villamarín, Xando, Fernández-Varón, Emilio, Rojas Romero, Michelle Carolina, Callejas-Rubio, José Luis, Cabeza-Barrera, José, Rodríguez-Nogales, Alba, Gálvez, Julio, Morón, Rocío

“…Azathioprine is commonly used as an immunosuppressive antimetabolite in the treatment of acute lymphoblastic leukemia, autoimmune disorders (such as Crohn's…”
Get full text

A New Pharmacogenetic Algorithm to Predict the Most Appropriate Dosage of Acenocoumarol for Stable Anticoagulation in a Mixed Spanish Population by Tong, Hoi Y, Dávila-Fajardo, Cristina Lucía, Borobia, Alberto M, Martínez-González, Luis Javier, Lubomirov, Rubin, Perea León, Laura María, Blanco Bañares, María J, Díaz-Villamarín, Xando, Fernández-Capitán, Carmen, Cabeza Barrera, José, Carcas, Antonio J

“…There is a strong association between genetic polymorphisms and the acenocoumarol dosage requirements. Genotyping the polymorphisms involved in the…”
Get full text

Analysing the In-Use Stability of mRNA-LNP COVID-19 Vaccines Comirnaty™ (Pfizer) and Spikevax™ (Moderna): A Comparative Study of the Particulate by Hermosilla, Jesús, Alonso-García, Airan, Salmerón-García, Antonio, Cabeza-Barrera, José, Medina-Castillo, Antonio L., Pérez-Robles, Raquel, Navas, Natalia

“…Comirnaty™ and Spikevax™ were the first vaccines approved for human use based on modified non-replicating mRNA lipophilic nanoparticle (mRNA-LNP) technology,…”
Get full text

Pharmacogenetics in the Treatment of Cardiovascular Diseases and Its Current Progress Regarding Implementation in the Clinical Routine by Dávila-Fajardo, Cristina Lucía, Díaz-Villamarín, Xando, Antúnez-Rodríguez, Alba, Fernández-Gómez, Ana Estefanía, García-Navas, Paloma, Martínez-González, Luis Javier, Dávila-Fajardo, José Augusto, Barrera, José Cabeza

“…There is a special interest in the implementation of pharmacogenetics in clinical practice, although there are some barriers that are preventing this…”
Get full text

Novel Genetic Variants Explaining Severe Adverse Drug Events after Clinical Implementation of DPYD Genotype-Guided Therapy with Fluoropyrimidines: An Observational Study by Díaz-Villamarín, Xando, Martínez-Pérez, María, Nieto-Sánchez, María Teresa, Ruiz-Tueros, Gabriela, Fernández-Varón, Emilio, Torres-García, Alicia, González Astorga, Beatriz, Blancas, Isabel, Iáñez, Antonio J, Cabeza-Barrera, José, Morón, Rocío

“…Fluoropyrimidines (FPs) are commonly prescribed in many cancer streams. The EMA and FDA-approved drug labels for FPs recommend genotyping the *2A (rs3918290),…”
Get full text

Compatibility of prolonged infusion antibiotics during Y‐site administration by Nunez‐Nunez, María, Murillo‐Izquierdo, Manuel, Moya‐Martin, Marisa, Hoxha, Malvina, Quesada Pérez, M. Teresa, Oltra‐Hostalet, Fernando, Alonso‐Ramos, Hector, Cordero‐Ramos, Jaime, Barrera‐Cabeza, Jose, Retamar‐Gentil, Pilar, Fernández‐del‐Castillo, Santiago Sandoval

“…Background Antimicrobial resistance is a threat to global public health. The use of prolonged infusions in the hospital setting for certain antimicrobials is…”
Get full text

Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy by Ríos-Tamayo, Rafael, Martín-García, Agustín, Alarcón-Payer, Carolina, Sánchez-Rodríguez, Dolores, de la Guardia, Ana María Del Valle Díaz, García Collado, Carlos Gustavo, Jiménez Morales, Alberto, Jurado Chacón, Manuel, Cabeza Barrera, José

“…Multiple myeloma is a very heterogeneous disease with variable survival. Despite recent progress and the widespread use of new agents, patients with relapsed…”
Get full text

Genetic risk factors for drug-induced liver injury in rheumatoid arthritis patients using low-dose methotrexate by Dávila-Fajardo, Cristina Lucía, Swen, Jesse J, Cabeza Barrera, José, Guchelaar, Henk-Jan

“…Low-dose methotrexate (MTX) is part of the mainstay of rheumatoid arthritis treatment. Hepatotoxicity is among the most feared side effects of low-dose MTX and…”
Get more information

Intact charge variant analysis of ziv-aflibercept by cationic exchange liquid chromatography as a proof of concept: Comparison between volatile and non-volatile salts in the mobile phase by Pérez-Robles, Raquel, Cuadros-Rodríguez, Luis, Salmerón-García, Antonio, Cabeza-Barrera, José, Navas, Natalia

“…•Comparative study of two CEX chromatographic methods for ziv-AFL charge variant analysis.•Method with volatile salts in mobile phase did not allow for…”
Get full text

The study protocol for a non-randomized controlled clinical trial using a genotype-guided strategy in a dataset of patients who undergone percutaneous coronary intervention with stent by Dávila-Fajardo, Cristina Lucía, Sánchez-Ramos, Jesús, Villamarín, Xando Diaz, Martínez-González, Luis Javier, Frías, Pablo Toledo, Huertas, Susana Martínez, Gómez, Francisco Burillo, Borrego, Juan Caballero, Pavés, Alicia Bautista, Guzmán, Mª Carmen Marín, Hernández, José Antonio Ramirez, Vilches, Concepción Correa, Barrera, Jose Cabeza

“…This article contains data related to the research article entitled “Results of genotype–guided antiplatelet therapy in patients undergone percutaneous…”
Get full text

Impact of single nucleotide polymorphisms on the efficacy and toxicity of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer patients by Pérez-Ramírez, Cristina, Cañadas-Garre, Marisa, Molina, Miguel Ángel, Cabeza Barrera, José, Faus-Dáder, María José

“…EGFR tyrosine kinase inhibitors (EGFR-TKIs) are the treatment of choice for advanced-stage (IIIB-IV) NSCLC patients with mutations in EGFR. However, EGFR-TKIs…”
Get full text

Extravasation accidents with liposomal/liposomal pegylated anthracyclines treated with dexrazoxane: an overview and outcomes by Caballero Romero, Álvaro, Delgado Ureña, María Teresa, Salmerón García, Antonio, Megías Fernández, María Teresa, Librada Porriño-Bustamante, María, Cabeza Barrera, José

“…The extravasation of chemotherapeutic agents is a challenge for oncologic care teams. The management of nonliposomal (conventional) anthracyclines is well…”
Get full text

Dalbavancin is a novel antimicrobial against Gram-positive pathogens: clinical experience beyond labelled indications by Núñez-Núñez, María, Casas-Hidalgo, Inmaculada, García-Fumero, Ricardo, Vallejo-Rodríguez, Inmaculada, Anguita-Santos, Francisco, Hernández-Quero, José, Cabeza-Barrera, José, Ruiz-Sancho, Andrés

“…Very limited labelled indications have been approved for the newer antimicrobials. Data on the clinical uses, efficacy and safety of dalbavancin are scarce,…”
Get full text

Confirmation of −174G/C interleukin-6 gene promoter polymorphism as a genetic marker predicting antitumor necrosis factor treatment outcome by Dávila-Fajardo, Cristina L, Márquez, Ana, Pascual-Salcedo, Dora, Moreno Ramos, Manuel J, García-Portales, Rosa, Magro, César, Alegre-Sancho, Juan J, Balsa, Alejandro, Cabeza-Barrera, José, Raya, Enrique, Martín, Javier

“…BACKGROUNDThe IL-6 –174G/C genetic variant has recently been associated with the clinical response to etanercept therapy in rheumatoid arthritis (RA) patients…”
Get full text

Gut Microbiota Composition Can Predict Colonization by Multidrug-Resistant Bacteria in SARS-CoV-2 Patients in Intensive Care Unit: A Pilot Study by García-García, Jorge, Diez-Echave, Patricia, Yuste, María Eugenia, Chueca, Natalia, García, Federico, Cabeza-Barrera, Jose, Fernández-Varón, Emilio, Gálvez, Julio, Colmenero, Manuel, Rodríguez-Cabezas, Maria Elena, Rodríguez-Nogales, Alba, Morón, Rocío

“…The SARS-CoV-2 infection has increased the number of patients entering Intensive Care Unit (ICU) facilities and antibiotic treatments. Concurrently, the…”
Get full text